Made Scientific Acquires Operational 85,000-Sq.-Ft. Cell Therapy GMP Facility in Pennsylvania
- Made Scientific closed acquisition of an operational 85,000-sq.-ft. cell therapy manufacturing facility in East Norriton, Pennsylvania from National Resilience on September 18, 2026.
- The facility has executed 145 GMP batches across autologous and allogeneic programs and includes eight Grade B/C cleanrooms, one Grade C ballroom, one Grade B fill-finish suite, and 30,000 sq. ft. of expansion space.
- Made Scientific plans to deploy 3D bioreactor platforms up to 200 liters, automated fill-finish, and lyophilization capacity; total U.S. East Coast footprint now reaches 145,000 sq. ft. with 15 qualified GMP suites.
Operational Impact
Made Scientific's acquisition of an operational facility with proven GMP batch history and immediate capacity eliminates ramp-up timelines for sponsors seeking 2027 clinical and commercial cell therapy supply, while the 30,000-sq.-ft. expansion plan and planned bioreactor/fill-finish upgrades position the East Norriton site as a scalable alternative to greenfield builds.
Source: PharmaSource RSS
Sanner Rebrands Gilero, Expands Chicago Innovation Facility
- Sanner completed rebranding of acquired Gilero under unified global brand following 2024 acquisition and U.S. manufacturing capacity investments.
- Chicago facility expansion adds human factors lab, 3D printing, prototyping capabilities, and partnership access to mHUB Innovation Center for medtech development acceleration.
Operational Impact
Sanner's Chicago facility expansion strengthens its medtech development footprint in the Midwest, reducing project risk and accelerating technology transfer for customers through integrated prototyping and human factors testing capabilities.
Source: Contract Pharma Breaking News RSS